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1 These authors contributed equally to this work.MicroRNA (miRNA) are a class of non-coding RNA that suppress gene expression by degradation or
translational inhibition of target RNA. Several miRNA have been shown to target oncogenes and
recently miRNA-125b was shown to translationally and transcriptionally inhibit the p53 gene. Here,
we show that an additional isomer of miRNA-125 (miRNA-125a) translationally arrests mRNA of the
p53 tumor suppressor gene. The basis of this activity is the high degree of sequence homology
between the seed sequence of miR-125a and the 30-UTR of p53. Our ﬁndings add miRNA-125a to
the growing list of miRNA with oncogenic targets.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
MicroRNA (miRNA) are a class of non-coding RNA that have
emerged as important regulators of gene expression. Although
identiﬁed nearly 25 years ago in the experimental organism Caeno-
rhabditis elegans, their biologic importance has only become appar-
ent recently [1–3]. Presently, some 721 miRNAs (Sanger miRbase;
Release 14.0) have been identiﬁed in humans but the list is likely a
vast underestimate according to recent bioinformatic investiga-
tions [4]. miRNA mediate posttranscriptional gene control by
either direct degradation or translational inhibition depending
upon the extent of sequence homology between miRNA and target
RNA [5,6].
The role of miRNA in human health and disease is under active
investigation. For example, extensive expression proﬁling of a large
number of primary human neoplasms has revealed unique miRNA
signatures associated with diseased tissue compared to surround-
ing healthy margins [7,8]. These miRNA species, termed oncomirs,
are thought to regulate a number of basic cellular processes in-
volved in neoplastic transformation and the clinical relevance of
these malignancy associated expression patterns is becomingchemical Societies. Published by E
ovirology, 55 Claverick Street
401 444 2939.
ratnam).increasingly apparent. Distinct miRNA proﬁles predict the natural
history of leukemia and lung cancer [9–11]. While detailed infor-
mation is rapidly emerging regarding neoplasm-speciﬁc miRNA
expression patterns, relatively little is known about their actual
gene targets.
Altered expression of miRNA-125b has been demonstrated in a
number of malignancies including prostate, breast and pancreatic
cancer [12,13]. In humans, two isoforms of miRNA-125 exist:
miR-125a and miR-125b1/b2 encoded in chromosomes 19, 11
and 21, respectively. Validated targets of miRNA-125b include
ERBB2/3 and BAK1 but numerous reports indicate that a single
miRNA may have hundreds if not thousands of targets [14,15]. Re-
cent reports have identiﬁed p53 and several of its upstream regu-
lators as a target of miRNA-125b [16]. Here, we extend these
ﬁndings and report that miRNA-125a also targets the p53 protein.
Unlike miRNA-125a, miRNA-125b appears to directly reduce p53
protein levels by translationally arresting p53 mRNA by binding
to homologous regions of the p53 30-UTR. In contrast to miRNA-
125b, ectopic expression of miRNA-125a has no effect upon the
transcriptional status of the p53 gene as mRNA levels are un-
changed. In further experimentation, we show that the p53-spe-
ciﬁc effects of miRNA-125a are independent of known negative
regulators of p53 such as Pirh2 and COP1. Finally, miRNA-125b
expression is associated with classic phenotypic and genotypic
sequelae of reduced p53 expression including altered sensitivity
to genotoxic agents and reduced expression of p53 relatedlsevier B.V. All rights reserved.
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miRNA-125a to the growing list of small RNA molecules that
may target p53 thus adding a further layer of complexity to the
regulation of the ‘‘guardian of the genome”.2. Materials and methods
2.1. Cell culture, transfection and molecular constructs
HEK 293T, HepG2 and MCF-7 cell lines were obtained from
American Type Culture Collection (ATCC). Cells were maintained
in growth media consisting of Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM) supplemented with 10% Fetal Bovine Serum. HEK 293T
cells and MCF-7 cells were transfected with plasmid DNA by using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instruction. HepG2 cells were transfected by using HepG2 transfec-
tion kit (Altogen Biosystems) according to the manufacturer’s
instructions.
Human miRNA-125a precursor was ampliﬁed from genomic
DNA by PCR (sense: 50-cgggatccggaccctgggaggaagag-30; antisense:
50-cggaattccagaggtcaggtttcagttggt-30) and cloned into RNAi-Ready
pSIREN-DNR (BD Biosciences Clontech) expression vector. Mature
miRNA-125a expression was conﬁrmed by Northern blot. Mutant
miRNA-125a plasmid was created by using QuikChange Site-Direc-
ted Mutagenesis Kit (Stratagene) (sense: 50-gttgccagtctctaggtgcgtg
agaccctttaacctg-30; antisense: 50-caggttaaagggtctcacgcacctagagact
ggcaac-30).
p53 30-UTR was ampliﬁed by PCR (sense: 50-ggactagtcag
aagggcctgactcagactga-30; antisense: 50-aaggaaaaaagcggccgcctctggg
aggctgagacaggtg-30) and cloned into the psiCHECK2 dual-luciferase
reporter plasmid (Promega).
2.2. Dual-luciferase reporter assays
Luciferase reporter assays were performed using the psiCHECK2
dual-luciferase reporter system. HEK 293T cells were co-transfec-
ted with psiCHECK2 plasmids and miRNA-125a expression vector
or empty vector. Fireﬂy and Renilla luciferase activities were quan-
tiﬁed using the Dual-Luciferase Reporter Assay System (Promega)
and Renilla luciferase activity was normalized to ﬁreﬂy luciferase
activity.
2.3. Western blot
Total cellular protein (20 lg)was separated by electrophoresis in
SDS–polyacrylamide gels before transfer to PVDF membrane
(Bio-Rad). The following primary antibodies were used: anti-p53
(Cell Signaling), anti-p21 (BD Pharmingen), Pirh2 (Santa Cruz
Biotechnology), COP1 (Santa Cruz Biotechnology). Signals were
visualized by chemiluminescence using the ECL-Plus reagent (GE
Healthcare).
2.4. Northern blot
Twenty-ﬁve micrograms total RNA was loaded on 15% acrylam-
ide gel and transferred onto Hybond N+ membrane (Ambion).
miRNA-125a probe (50-tccctgagaccctttaacctgtgacctgtctc-30) was la-
beled by using Biotin RNA labeling kit (Roche). Hybridization was
carried out at 42 C for 12 h and signal was detected by BrightStar
BioDetect kit (Ambion).
2.5. RT-PCR quantiﬁcation
Total RNA was extracted by TRIZOL and 1 lg RNA was used for
cDNA synthesis using MMLV reverse transcriptase (New EnglandBiolabs) with random primers. PCR analysis was performed by
RT2 Real-TimeTM SYBR Green PCR master mix (SuperArray) accord-
ing to the manufacturer’s protocol using the Eppendorf realplex2
Mastercycler machine (Eppendorf). Results were normalized by
beta-actin (sense: 50-gcc agg tca tca cca ttg-30; antisense: 50-gga
agg aag gc tgg aag a-30). Primers using for miRNA-34a, 34b and
34c primary/precursor quantiﬁcation are as follows: pri-miRNA-
34a (sense: 50-ccc cac att tcc ttc tta tca ac-30; antisense: 50-cccca-
catttccttcttatcaac-30); pre-miRNA-34a (sense: 50-cag tgt ctt agc
tgg ttg ttg tgag-30; antisense: 50-gccagtatacttgctgattgcttc-30);
pri-miRNA-34b (sense: 50-gcg tcc ctc gg tga aatgg-30; antisense:
50-cgcttctcaggcatcttctctc-30); pre-miRNA-34b (sense: 50-ggcagtgt-
cattagctgattgtactg-30; antisense: 50-gggcagtggacttagtgattgtaac-30);
pri-miRNA-34c (sense: 50-gcctgcctgtcacaacgtg-30; antisense:
50-gcacaggcagctcatttggac-30); pre-miRNA-34c (sense: 50-aggcagtg-
tagttagctgattgc-30; antisense: 50-ggccgtgtggttagtgattg-30).
TaqMan microRNA assays (Applied Biosystems) that include
RT primers and TaqMan probes were used to quantify the levels
of mature miRNA. All PCR reactions were run in triplicate.
2.6. Measurement of cell viability and proliferation
HepG2 cells were transfected with an empty vector (EV), p53
siRNA and miRNA-125a. After overnight incubation, the cells were
treated with or without 10 lM arsenic trioxide (ATO, Sigma) for
48 h. Cell viability and proliferation were measured with an MTT
Cell Proliferation Assay kit (ATCC) and BrdU Proliferation Assay
kit (CalBiochem) following the manufacturer’s instructions,
respectively.3. Results and discussion
3.1. miRNA-125a targets the 30-UTR of p53
Using a recently developed pattern based miR target identiﬁca-
tion algorithm (Rna22), we found that the 30-UTR of p53 harbors a
sequence motif that is identical to the seed sequence (nucleotides
2–7 from the 50-end) of miRNa-125a (Fig. 1a) [17]. Both isoforms
125a and 125b share perfect sequence homology in this seed se-
quence but vary towards the 30-end of the mature miR molecule
(Fig. 1a). We constructed a miRNA-125a expression vector by
inserting a 365 nt long fragment of pri-miRNA-125a into a generic
CMV promoter driven plasmid. Northern blot and Real Time PCR
for mature miR-125a conﬁrmed ectopic over-expression in vector
transfected cells compared to relevant controls which included
an empty vector or one encoding an irrelevant miRNA (Fig. 1b).
To determine whether miR-125a targets the 30-UTR of p53, PCR
was used to amplify the 1185 nt long 30-UTR of p53 from human
genomic DNA and the resulting amplicon was inserted into a lucif-
erase reporter vector. Transfection of miRNA-125a and luciferase
vectors into HEK 293T cells led to the 40% reduction in normalized
luciferase values compared to relevant controls including an empty
miRNA expression plasmid (Fig. 1c). The stringency of miRNA-125a
sequence homology was next tested by creating miRNA-125a vari-
ants with nucleotide mutations at 50 positions 2 and 4 of the seed
sequence. When these constructs were introduced into cells along
with the p53 30-UTR luciferase system, activity was abrogated
compared to transfections involving wild-type miRNA-125a
(Fig. 1c).
3.2. miRNA-125a translationally arrests p53 mRNA
To determine whether ectopic expression of miRNA-125a de-
creases p53 protein levels, we transfected HEK 293T cells with an
miRNA-125a expression vector. As seen in Fig. 2a, p53 protein
Fig. 1. miR-125 targets the 30-UTR of p53. (a) The p53-miRNA-125a/b interactome: both isomers of miR-125 (125a, 125b) share homology in their seed sequence (50 nt 2–7)
with the 30-UTR of p53. (b) Ectopic miRNA-125a expression vector. HEK 293T cells were transfected with miRNA-125a expression vector or control vectors that harbored
either irrelevant DNA construct encoding miRNA-378 or no insert (EV). Levels of mature miRNA-125a were visualized by Northern blot (left panel) and quantiﬁed by Real
Time PCR (right panel). Both assays revealed that wild-type HEK 293T cells express low levels of miRNA-125a that were increased by 12-fold upon transfection of miRNA-
125a as quantiﬁed by Real Time PCR in three independent experiments (results are reported as mean values ± S.D.). (c) Regulation of the p53 30-UTR by miRNA-125a. Activity
of miRNA-125a on the 30-UTR of p53 was initially assessed by luciferase based reporter assays. The p53 30-UTR was incorporated into the ﬁreﬂy luciferase gene and run off a
single promoter. A constitutively expressed Renilla gene served to normalize transfections. All constructs were introduced into HEK 293T cells with miRNA-125a or an empty
control vector (EV) and luminescence was measured at 48 h. miRNA-125a reduced luciferase levels by 40%. The sequence speciﬁcity of miRNA-125a/p53 30-UTR interaction
was probed by mutating the seed sequence of miRNA-125a in positions 2 and 4. In comparison to wild-type miRNA-125a, the mutated version had negligible effect (<5%) on
the p53 30-UTR as quantiﬁed by levels of luciferase reduction after transfection. Data are presented as mean fold reduction ± S.D. All experiments were performed in triplicate.
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had been transfected by an empty vector or one encoding an irrel-
evant miRNA. Recent reports indicate that numerous potential
interactions may exist between various miRNA species and the
p53 network. For example, a bioinformatics based approach iden-
tiﬁed 115 miRNA, including miRNA-125b, that are predicted to tar-
get upstream or downstream regulators of p53 [18]. Interestingly,
laboratory based investigation revealed that miRNA-125b did in
fact share sequence homology and functionally target six genesthat are upstream regulators of p53 [16]. Indeed, miRNA-125b
expression was associated with decreased p53 mRNA levels. Thus,
ectopic expression of miRNA-125b decreases p53 levels not only
by translational inhibition but also by directly targeting p53 tran-
scriptional regulators. To determine whether a similar effect was
associated with miRNA-125a, we quantiﬁed p53 mRNA levels in
cells transfected with miRNA-125a or control expression vectors.
As seen in Fig. 2a, ectopic expression of miRNA-125a had no effect
on p53 mRNA levels as quantiﬁed by Real Time PCR thus support-
Fig. 2. miRNA-125a reduces p53 protein levels by translational arrest of p53 mRNA. (a) Ectopic expression of miRNA-125a reduces p53 protein expression in HEK 293T cells
by translational arrest. Cells were transfected with expression vectors for miRNA-125 or an irrelevant construct encoding miRNA-378 and p53 protein levels were quantiﬁed
by Western blot. GAPDH levels were used to normalize protein input (upper panel). p53 protein reduction by miRNA-125a was not associated with reduction in p53 mRNA
levels as quantiﬁed by Real Time PCR in cells that had been treated with an empty vector or one encoding miRNA-125a. Data are presented as mean fold reduction ± S.D. All
experiments were performed in triplicate. (b) Efﬁcacy of miRNA-125a approaches that of p53 short interfering RNA (siRNA). p53 protein levels were quantiﬁed by Western
blot in a breast cancer cell line (MCF-7) that had been transfected with either p53 speciﬁc siRNA or miRNA-125a. Both agents reduced protein levels of both p53 and
downstream protein p21. GAPDH levels were used to normalize protein input. (c) The effect of p53 levels themselves on miRNA-125a was examined in three cell lines.
Reduction of p53 protein levels by siRNA had no effect upon levels of endogenously expressed miRNA-125a (upper panel) or miRNA-125b (lower panel) when compared to
cells that had been treated with a control empty vector (EV). (d) Several proteins including COP1 and Prih2 are known to negatively regulate p53 protein levels. We found that
ectopic expression of miRNA-125a had no effect on levels of either protein, as assessed by Western blot.
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Similar results were observed when the experiment was repeated
in MCF-7 cells (data not shown). miRNA-125a proved almost as
efﬁcacious as speciﬁc siRNA against p53 in reducing protein levels
(Fig. 2b). As expected, decreased levels of p53 by miRNA-125a or
siRNA targeting p53 was associated with decreased levels of p21,
a downstream target of p53 (Fig. 2b). We next asked whether the
p53 protein itself was involved in the biogenesis of miRNA-125b.RNAi mediated depletion of p53 had no effect upon endogenous
mature miRNA-125a levels in the three cell lines examined. A sim-
ilar result was also apparent for miRNA-125b (Fig. 2c). Given that
levels of p53 are inﬂuenced my negative regulators such as Prih2
and COP1, we quantiﬁed levels of these proteins in cells over
expressing miRNA-125a. As seen in Fig. 2d, miRNA-125a
over-expression did not alter Prih2 or COP1 levels, as assessed by
Western blot.
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Fig. 3. p53-speciﬁc genotypic and phenotypic sequelae of miR-125a expression. (a)
p53-speciﬁc genotypic sequelae of miRNA-125a expression. miRNA-34a/b/c have
been established as transcriptional targets of p53. Levels of all three miRNAs were
reduced by 20–80% in cells over expressing miRNA-125a as quantiﬁed by Real Time
PCR of mature (upper panel) and pri-miRNA levels (lower panel). Data are
presented as mean fold reduction ± S.D. compared to cells treated with an empty
vector (EV). All experiments were performed in triplicate. (b) p53-speciﬁc
phenotypic sequelae of miRNA-125a expression. Over-expression of miRNA-125a
protects cells from cell death induced by arsenic trioxide. Cells were treated with
arsenic trioxide and their viability was quantiﬁed by MTT assay. As expected, EV
treated cells could not withstand the toxicity of arsenic trioxide. Pre-treatment of
cells with siRNA targeting p53 or miRNA-125a preserved viability. All experiments
were performed in triplicate and the average and standard deviation of viable cells
is shown. (c) The response to arsenic trioxide was assessed by BrdU assay in cells
with p53 knockdown or in cells treated with an irrelevant empty vector or one
encoding miRNA-125a. Arsenic trioxide or its absence was not related to any
signiﬁcant differences in cellular proliferative capacity in any of the six conditions
tested.
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over-expression
The p53 protein is involved in a myriad processes central to cel-
lular health. We next used a variety of experimental conditions to
quantify the effect of miRNA-125a expression on the phenotypic
and genotypic sequelae of p53 down modulation. The transcrip-
tional activity of p53 has been well characterized vis a vis its reg-
ulation of cell cycle checkpoints. A number of recent investigations
have revealed that p53 induces the transcription of the miRNA-34
family, comprised of miR-34a, -34b and -34c. To determine
whether a similar regulatory circuit could be enforced by miRNA-
125a over-expression, we quantiﬁed the levels of miRNA-34a/b/c
by stem-loop quantitative reverse transcription-PCR (RT-PCR) in
control cells or those that over expressed miRNA-125a. As seen
in Fig. 3a, levels of miRNA-34a/b/c were reduced by ectopic expres-
sion of miRNA-125a, albeit at different levels with the most dra-
matic reduction seen for miRNA-34c. As expected, a concomitant
decrease in pri-miRNA-34a/b/c levels was also observed upon ecto-
pic expression of miRNA-125a.
Genotoxic stressors such as irradiation or drugs such as arsenic
trioxide lead to apoptosis in a p53 dependent manner. For exam-
ple, treatment of HepG2 cells with arsenic trioxide leads to a
marked decrease in cellular survival as quantiﬁed by MTT assay.
Using this system, we ﬁrst probed the impact of miRNA-125a on
the cellular response to arsenic trioxide. Lipid transfection of miR-
NA-125a or short interfering RNA targeting p53 protected arsenic
trioxide cells from cell death in contrast to cells that had been trea-
ted with control constructs (Fig. 3b). These data were further bol-
stered by the parallel performance of a BrdU proliferation assay.
We could detect no difference in the extent of cellular proliferation
in cells with ectopic expression of miRNA-125a compared to rele-
vant controls (Fig. 3c). Thus, our data in sum suggest that miRNA-
125a can decrease p53 protein in human cells and that this reduc-
tion is associated with p53-speciﬁc phenotypic and genotypic se-
quelae. Interestingly, miR-125a/b is one of the handful of miRs
that are conserved in ﬂies, worms and mammals, similar to miR-
NA-34, thus suggesting that miRNA/p53 interactions are evolved
processes [19].
As mentioned, a number of miRNAs have been implicated in the
natural history of malignant disease and have the potential of serv-
ing as clinically useful biomarkers [9]. More recently, miRNA
expression patterns have been associated with response rates to
chemotherapy of colon cancer where high miRNA-21 expression
levels were associated with poor clinical response to ﬂuorouracil
based adjuvant therapy [20]. Recently, levels of miRNA-125 have
been reported to be upregulated in the majority of rectal cancer
and associated with a poorer response to multi-modal therapy
including pre-operative capecitabine, surgery and radiotherapy
[21]. Our results suggest that miRNA-125a may impact response
to treatments that rely upon functional p53 expression and merits
further study, especially with respect to the cellular cues that lead
to the transcriptional activation of the miRNA-125a locus. Such
investigations may reveal upstream regulators of a locus that di-
rectly impacts p53 levels.
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